EUVIMEDEUVIMED entdecken
Crossref

Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate

Hui He, Xiaoling Chen, Yueqiu Chen, Qingpeng Li, Fan Yang, Lin Zhou

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2026.116359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Hui He und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates, Single-Chain Antibodies, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Guangdong Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cell cycle regulator p16 is overexpressed in multiple cancers, and its elevated expression frequently correlates with aggressive tumor behavior and poor prognosis. However, the development of therapeutic agents directly targeting p16 has remained challenging. Antibody-drug conjugates (ADCs) represent an established modality for targeted drug delivery. To explore alternative formats that may address inherent challenges of conventional ADCs-such as potentially limited tumor penetration due to their large size and the risk of immunogenicity associated with the Fc domain-we engineered a novel p16-targeting antibody fragment-drug conjugate (AFDC). This conjugate is based on a humanized single-chain variable fragment (scFv) fused to a cell-penetrating peptide, aiming to achieve efficient intracellular delivery of the cytotoxic payload doxorubicin via p16-mediated targeting. We isolated five unique p16-specific scFvs from hybridoma cells. Following humanization, each was fused with a cell-penetrating peptide (CPP) S413 to construct scFv-p16-S413 variants. Following affinity assessment, scFv-p16-S413-04 was selected as the backbone and conjugated to doxorubicin via a chemical linker to generate the AFDC. In cellular assays, the resulting AFDC exhibited a p16 expression-dependent selectivity, showing stronger cytotoxicity against p16-high cancer cells (HeLa, BT-549) than against p16-low cells (MDA-MB-231, LO2, HEK-293 T). This selective activity correlated with target-dependent internalization. Furthermore, in p16-positive triple-negative breast cancer (TNBC) organoid models, AFDC treatment markedly reduced cell viability, underscoring its potent antitumor activity. Collectively, this proof-of-concept study supports the potential therapeutic value of a p16-targeted AFDC for p16-high tumors and illustrates the viability of the AFDC platform as an emerging strategy to target intracellular proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImmunoconjugatesSingle-Chain AntibodiesCyclin-Dependent Kinase Inhibitor p16NeoplasmsTriple Negative Breast NeoplasmsHeLa CellsMDA-MB-231 CellsHEK293 CellsHumansOrganoidsCell-Penetrating Peptides

Stichwörter der Autor:innen

AFDCMonoclonal antibodyOrganoidTargeted therapyp16 proteinscFv

Substanzen

Antineoplastic AgentsImmunoconjugatesSingle-Chain AntibodiesCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cell-Penetrating Peptides

Autor:innen und Institutionen

  • School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
  • School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Guangdong Pharmaceutical University,…
  • School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China; Guangdong Provincial…

Förderung

  • Guangdong Pharmaceutical University

Zitieren

APA

He, H., Chen, X., Chen, Y., Li, Q., Yang, F., & Zhou, L. (2026). Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116359

Vancouver

He H, Chen X, Chen Y, Li Q, Yang F, Zhou L. Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116359

BibTeX
@article{He2026,
  author = {He, Hui and Chen, Xiaoling and Chen, Yueqiu and Li, Qingpeng and Yang, Fan and Zhou, Lin},
  title = {Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2026.116359}
}
Kostenlos starten →